Results 11 to 20 of about 50,409 (184)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Targeting RTK signaling pathways in cancer [PDF]

, 2015
The RAS/MAP kinase and the RAS/PI3K/AKT pathways play a key role in the regulation of proliferation, differentiation and survival. The induction of these pathways depends on Receptor Tyrosine Kinases (RTKs) that are activated upon ligand binding.
Regad, T
core   +1 more source

An extremely rare case of concurrent BRAF V600E mutation driven hairy cell leukemia and melanoma: case report and review of literature

Autopsy and Case Reports, 2017
BRAF protein is a serine/threonine kinase with 766 amino acids. Approximately 15% of human cancers harbor BRAF mutations as well as other BRAF anomalies (amplifications, fusions).
Amir Ghorbani-Aghbolaghia, Mirna Lechpammer, Saba F. Ali, Nam K. Ku, Denis M. Dwyre, Hooman H. Rashidi   +5 more
doaj   +1 more source

The addition of PD-1/PD-L1 axis blockade to BRAF and MEK inhibition for advanced melanoma patients harboring BRAF mutations: a systematic review and meta-analysis

Brazilian Journal of Oncology, 2022
Objectives: Immune-checkpoint inhibitors (ICI) and targeted-therapies (TT) have become standard options for BRAF-V600 metastatic melanomas (MM). Recently, randomized trials (RCT) addressed the efficacy of combined approaches, with conflicting results. We
Mauricio Fernando Silva Almeida Ribeiro, Camila Bragança Xavier, Allan Andresson Lima Pereira, Mariana Scaranti, Luiza Dib Batista Bugiato Faria, Tatiana Strava Correa, Marina Sahade, David Queiroz Borges Muniz, Olavo Feher, Gustavo dos Santos Fernandes, Artur Katz, Rodrigo Ramella Munhoz   +11 more
doaj   +1 more source

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

Metanephric Adenoma with cystic changes- An uncommon presentation of a rare tumor in a young adult

Autopsy and Case Reports, 2021
Metanephric adenoma (MA) is a rare benign neoplasm of the kidney that is usually asymptomatic and incidentally diagnosed. MA usually present as a solid mass; however, a cystic presentation has been reported.
Darilin Shangpliang, Pakesh Baishya, Jaya Mishra, Evarisalin Marbaniang, Biswajit Dey, Baphira Wankhar, Ronika Saikia   +6 more
doaj  

FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells [PDF]

, 2014
Receptor Tyrosine Kinases (RTKs) and Focal Adhesion Kinase (FAK) regulate multiple signalling pathways, including mitogen-activated protein (MAP) kinase pathway. FAK interacts with several RTKs but little is known about how FAK regulates their downstream
A Bergmann, A Boulay, A Ueda, AC Dar, B Corkery, B Gabriel, BA Edgar, BA Hay, BJ Dickson, C Grabbe, CJ Marshall, D Tenenbaum, DD Schlaepfer, DJ Sieg, E Macia, E Rainero, E Rainero, E Sandilands, E Sandilands, Emma Sandilands, FD Karim, FJ Diaz-Benjumea, G Adam, GL Fox, I Bongarzone, I Plaza-Menacho, I Rebay, Iain MacPherson, IH Gelman, J Cordero, J Fujimoto, J Verdu, J Zhao, Jesica Diaz Vera, Jim C. Norman, JR Infante, JT Parsons, JT Price, Juan Pablo Macagno, K Blochlinger, K Halfar, K Mesaki, K Sawamoto, L Henriksen, L Sadowski, LV Owens, M Agochiya, M Ayaki, M Freeman, M Grieco, M Miaczynska, M Roberts, M Santoro, M Therrien, M Vidal, M Vidal, Marcos Vidal, Margaret Frame, Marshall S. Horwitz, MC Frame, ME Grether, ME Irwin, MM Bradford, P Kurada, P-I Tsai, PM Siesser, R Gleichauf, R Ohta, RD Read, RH Palmer, Ruth Palmer, S Leboulleux, S Murakami, S Rizzolio, S Sigismund, SA Speicher, SM Jhiang, SY Chen, T Das, T Matsuo, T-H Chen, W Long, WG Cance, X Zhao, Y Zheng, Yachuan Yu, Z Lu   +86 more
core   +4 more sources

IAPs on the move : role of inhibitors of apoptosis proteins in cell migration [PDF]

, 2013
Inhibitors of Apoptosis Proteins (IAPs) are a class of highly conserved proteins predominantly known for the regulation of caspases and immune signaling. However, recent evidence suggests a crucial role for these molecules in the regulation of tumor cell
Murali, Arun, Oberoi-Khanuja, Tripat Kaur, Rajalingam, Krishnaraj   +2 more
core   +1 more source

The benefit of co-targeting PARP-1 and c-Met on the efficacy of radiotherapy in wild type BRAF melanoma

Frontiers in Medicine, 2023
Melanoma is known to be a radioresistant cancer. Melanoma radioresistance can be due to several factors such as pigmentation, antioxidant defenses and high Deoxyribonucleic acid (DNA) repair efficacy.
Malak Sabbah, Ahmad Najem, Christophe Vanderkerkhove, Fabien Kert, Younes Jourani, Fabrice Journe, Ahmad Awada, Dirk Van Gestel, Ghanem E. Ghanem, Mohammad Krayem, Mohammad Krayem   +10 more
doaj   +1 more source

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]

, 2019
A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core   +2 more sources